Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 Biomarker disease BEFREE Deletion and mutation, usually associated, of ATM or TP53 are frequent in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma. 28284458 2017
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 GeneticVariation disease BEFREE ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma. 27823642 2016
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 Biomarker disease BEFREE A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function. 25232030 2015
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 GeneticVariation disease BEFREE The MEC-1 and GRANTA-519 cells can be especially recommended for in vivo study of p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma, respectively. 25827173 2015
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 Biomarker disease BEFREE We previously reported that mantle cell lymphoma cells with deficiency in ataxia telangiectasia mutated (ATM) are sensitive to PARP-1 inhibitors in vitro and in vivo. 24841718 2014
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 Biomarker disease BEFREE Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks. 22170260 2012
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 Biomarker disease GENOMICS_ENGLAND Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. 19781682 2009
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 AlteredExpression disease BEFREE Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. 16461462 2006
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 AlteredExpression disease BEFREE The cell cycle, the ATM, gene and the nuclear factor kappaB pathways are the main targets of the genetic abnormalities occurring in mantle cell lymphoma: new genomic and expression data have been recently published. 15548996 2004
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 Biomarker disease BEFREE In B-chronic lymphocytic leukemia and mantle cell lymphoma we observed two categories: ATM-negative tumors, most likely reflecting the presence of ATM mutation, and tumors with abundant ATM expression. 12875964 2003
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 PosttranslationalModification disease BEFREE ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. 11756177 2002
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 Biomarker disease BEFREE The ATM gene in the pathogenesis of mantle-cell lymphoma. 10707794 2000
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 GeneticVariation disease BEFREE A hemizygous ATM deletion was seen in 44% to 88% of the interphase cells in 15 cases (11.1%); four patients had an indolent lymphoma (follicular center cell lymphoma), and 11 patients had an aggressive lymphoma (five mantle-cell lymphomas [MCLs] and six diffuse large-cell lymphomas). 10893293 2000
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 GeneticVariation disease BEFREE To investigate a potential pathogenic role of ATM in B-cell tumorigenesis, we performed mutation analysis of ATM in 29 malignant lymphomas of B-cell origin (B-CLL = 27; mantle cell lymphoma, [MCL] = 2). 10397742 1999
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 PosttranslationalModification disease BEFREE Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. 10556216 1999
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 Biomarker disease GENOMICS_ENGLAND
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 CausalMutation disease CGI
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 CausalMutation disease CLINVAR
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
0.800 GeneticVariation disease UNIPROT